AU2019398451A1 - Amorphous solid dispersions - Google Patents
Amorphous solid dispersions Download PDFInfo
- Publication number
- AU2019398451A1 AU2019398451A1 AU2019398451A AU2019398451A AU2019398451A1 AU 2019398451 A1 AU2019398451 A1 AU 2019398451A1 AU 2019398451 A AU2019398451 A AU 2019398451A AU 2019398451 A AU2019398451 A AU 2019398451A AU 2019398451 A1 AU2019398451 A1 AU 2019398451A1
- Authority
- AU
- Australia
- Prior art keywords
- dispersion
- iti
- dioxane
- methanol
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862779930P | 2018-12-14 | 2018-12-14 | |
US62/779,930 | 2018-12-14 | ||
PCT/US2019/066247 WO2020123952A1 (en) | 2018-12-14 | 2019-12-13 | Amorphous solid dispersions |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2019398451A1 true AU2019398451A1 (en) | 2021-07-15 |
Family
ID=71077112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019398451A Pending AU2019398451A1 (en) | 2018-12-14 | 2019-12-13 | Amorphous solid dispersions |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3893878A4 (ko) |
JP (1) | JP7523440B2 (ko) |
KR (1) | KR20210103501A (ko) |
CN (1) | CN113473988A (ko) |
AU (1) | AU2019398451A1 (ko) |
CA (1) | CA3123085A1 (ko) |
IL (1) | IL283927A (ko) |
MX (1) | MX2021006886A (ko) |
WO (1) | WO2020123952A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210052471A (ko) * | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2901375T3 (es) * | 2016-08-09 | 2022-03-22 | Teva Pharmaceuticals Int Gmbh | Formas en estado sólido de sal de ditosilato de lumateperona |
CN110072518B (zh) * | 2016-10-12 | 2021-10-26 | 细胞内治疗公司 | 无定形固体分散体 |
EP3609501A4 (en) * | 2017-04-10 | 2020-08-19 | Dr. Reddy's Laboratories Limited | AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE |
EP3717484A4 (en) * | 2017-11-27 | 2021-08-04 | Egis Gyógyszergyár Zrt. | PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT |
KR20210052471A (ko) * | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
-
2019
- 2019-12-13 MX MX2021006886A patent/MX2021006886A/es unknown
- 2019-12-13 AU AU2019398451A patent/AU2019398451A1/en active Pending
- 2019-12-13 KR KR1020217021918A patent/KR20210103501A/ko active Search and Examination
- 2019-12-13 CN CN201980092118.2A patent/CN113473988A/zh active Pending
- 2019-12-13 JP JP2021533470A patent/JP7523440B2/ja active Active
- 2019-12-13 CA CA3123085A patent/CA3123085A1/en active Pending
- 2019-12-13 WO PCT/US2019/066247 patent/WO2020123952A1/en unknown
- 2019-12-13 EP EP19897052.7A patent/EP3893878A4/en active Pending
-
2021
- 2021-06-13 IL IL283927A patent/IL283927A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210103501A (ko) | 2021-08-23 |
EP3893878A4 (en) | 2022-08-17 |
EP3893878A1 (en) | 2021-10-20 |
IL283927A (en) | 2021-07-29 |
JP7523440B2 (ja) | 2024-07-26 |
MX2021006886A (es) | 2021-09-14 |
WO2020123952A1 (en) | 2020-06-18 |
CA3123085A1 (en) | 2020-06-18 |
JP2022512239A (ja) | 2022-02-02 |
CN113473988A (zh) | 2021-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11872223B2 (en) | Amorphous solid dispersions | |
TWI719349B (zh) | Cftr調節劑之結晶形式及組合物 | |
BR112020014487A2 (pt) | composições farmacêuticas para tratamento de fi-brose cística | |
WO2020242935A1 (en) | Methods of treatment for cystic fibrosis | |
WO2019113089A1 (en) | Compositions for treating cystic fibrosis | |
EP3243824A1 (en) | Solid forms of ibrutinib free base | |
US10660963B2 (en) | Pharmaceutical composition containing tacrolimus and preparation methods thereof | |
EP2742940A1 (en) | Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily | |
IL298523A (en) | Solid forms of perletinib | |
JP7523440B2 (ja) | アモルファス固体分散体 | |
SI22750A (sl) | Ivabradin hidrobromid | |
KR101288001B1 (ko) | 모사프라이드를 유효성분으로 함유하는 서방성 제제 | |
KR101823071B1 (ko) | 텔미사르탄-함유 정제의 제조방법 | |
WO2016169534A1 (en) | Solid forms of amorphous empagliflozin | |
Desai et al. | Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules | |
Shete et al. | Studies on effect of hydrophilic polymers on physicochemical properties of itraconazole cocrystals | |
CA2890470A1 (en) | Solid dispersions of insoluble drug and preparation method thereof | |
CA3031777A1 (en) | Crystalline form of olaparib | |
US9211290B2 (en) | Solid dispersions of amorphous paroxetine mesylate | |
US20120190662A1 (en) | Pharmaceutical propylene glycol solvate compositions | |
KR100805675B1 (ko) | 클로피도그렐 베실레이트를 포함하는 약학 조성물 및 그의제조방법 | |
TW202302597A (zh) | 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途 | |
JP2018509375A (ja) | アジルサルタンメドキソミルのカリウム塩を調製するプロセス |